TY - JOUR
T1 - A Multicenter Prospective Study Evaluating Efficacy and Safety of a Single-incision Sling Procedure for Stress Urinary Incontinence
AU - Erickson, Ty
AU - Roovers, Jan-Paul
AU - Gheiler, Edward
AU - Parekh, Mitesh
AU - Parva, Mohamad
AU - Hanson, Craig
AU - McCrery, Rebecca
AU - Tu, Le Mai
N1 - Funding Information: The funding was provided by Coloplast Corp, Minneapolis, Minnesota. Publisher Copyright: © 2020 AAGL
PY - 2021/1
Y1 - 2021/1
N2 - Study Objective: The aim of the Altis 522 study was to compare the safety and efficacy of the Altis Single-Incision Sling System (SIS) (Coloplast, Minneapolis, MN) with standard midurethral transobturator and/or retropubic slings through 36 months. In this report, we present data through 12 months of follow-up. Design: Postmarket, prospective, multicenter, nonrandomized cohort design. Setting: The study was performed at 23 hospitals in the United States and Canada. Patients: Adult female patients with stress urinary incontinence (SUI) clinically indicated for an incontinence sling were treated (n = 355). Interventions: Altis SIS was compared with any Food and Drug Administration–cleared transobturator or retropubic sling. Measurements and Main Results: Collected measures included device- and/or procedure-related serious adverse events, relevant nonserious and all adverse events, and revision surgery. Objective efficacy measures included 24-hour pad weight, dryness (defined as pad weight ≤4.0 g), and cough stress test. Subjective outcome measures included patient global impression of improvement, urogenital distress inventory, Incontinence Impact Questionnaire–Short Form, Surgical Satisfaction Questionnaire, and visual analog scale for pain. At 12 months, 24-hour pad weight success (≥50% reduction), negative cough stress test, patient global impression of improvement, urogenital distress inventory, and Incontinence Impact Questionnaire–Short Form appeared similar between groups. Through 12 months, 2 subjects in the Altis group and 3 subjects in the comparator group experienced a serious device- and/or procedure-related adverse event. In the Altis group, 1 subject (0.5%) experienced a device revision, and 1 subject (0.5%) had the device explanted. In the comparator group, 7 subjects (4.1%) experienced a device revision, and 1 device (0.6%) was explanted before the 12-month visit. The occurrence of relevant nonserious procedure and/or device-related adverse events was similar between groups. Conclusion: At 12-months follow-up, safety and efficacy appeared similar between Altis SIS and standard transobturator and retropubic midurethral slings.
AB - Study Objective: The aim of the Altis 522 study was to compare the safety and efficacy of the Altis Single-Incision Sling System (SIS) (Coloplast, Minneapolis, MN) with standard midurethral transobturator and/or retropubic slings through 36 months. In this report, we present data through 12 months of follow-up. Design: Postmarket, prospective, multicenter, nonrandomized cohort design. Setting: The study was performed at 23 hospitals in the United States and Canada. Patients: Adult female patients with stress urinary incontinence (SUI) clinically indicated for an incontinence sling were treated (n = 355). Interventions: Altis SIS was compared with any Food and Drug Administration–cleared transobturator or retropubic sling. Measurements and Main Results: Collected measures included device- and/or procedure-related serious adverse events, relevant nonserious and all adverse events, and revision surgery. Objective efficacy measures included 24-hour pad weight, dryness (defined as pad weight ≤4.0 g), and cough stress test. Subjective outcome measures included patient global impression of improvement, urogenital distress inventory, Incontinence Impact Questionnaire–Short Form, Surgical Satisfaction Questionnaire, and visual analog scale for pain. At 12 months, 24-hour pad weight success (≥50% reduction), negative cough stress test, patient global impression of improvement, urogenital distress inventory, and Incontinence Impact Questionnaire–Short Form appeared similar between groups. Through 12 months, 2 subjects in the Altis group and 3 subjects in the comparator group experienced a serious device- and/or procedure-related adverse event. In the Altis group, 1 subject (0.5%) experienced a device revision, and 1 subject (0.5%) had the device explanted. In the comparator group, 7 subjects (4.1%) experienced a device revision, and 1 device (0.6%) was explanted before the 12-month visit. The occurrence of relevant nonserious procedure and/or device-related adverse events was similar between groups. Conclusion: At 12-months follow-up, safety and efficacy appeared similar between Altis SIS and standard transobturator and retropubic midurethral slings.
KW - Efficacy
KW - Minimal invasive
KW - Postmarketing study
KW - Safety
KW - Single-incision midurethral sling surgery
KW - Stress urinary incontinence
KW - Surgery
UR - http://www.scopus.com/inward/record.url?scp=85085110094&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jmig.2020.04.014
DO - https://doi.org/10.1016/j.jmig.2020.04.014
M3 - Article
C2 - 32320798
SN - 1553-4650
VL - 28
SP - 93
EP - 99
JO - Journal of Minimally Invasive Gynecology
JF - Journal of Minimally Invasive Gynecology
IS - 1
ER -